Comparison 1. 5‐FU versus Placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Cure	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1.1 Female plus Male	3	209	Risk Ratio (M‐H, Random, 95% CI)	0.39 [0.23, 0.67]
1.1.2 Female	3	179	Risk Ratio (M‐H, Random, 95% CI)	0.41 [0.20, 0.82]
1.1.3 Male	1	30	Risk Ratio (M‐H, Random, 95% CI)	0.38 [0.16, 0.91]
1.2 Cure for number of genital warts	1	312	Risk Ratio (M‐H, Random, 95% CI)	6.22 [4.16, 9.28]
1.3 Partial Response / Melhora	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.3.1 Female plus Male	1	59	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.74, 1.17]
1.3.2 Female	1	29	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.65, 1.47]
1.3.3 Male	1	30	Risk Ratio (M‐H, Random, 95% CI)	0.91 [0.71, 1.17]
1.4 Absence of Response	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.4.1 Female plus Male	1	59	Risk Ratio (M‐H, Random, 95% CI)	0.34 [0.16, 0.74]
1.4.2 Female	1	29	Risk Ratio (M‐H, Random, 95% CI)	0.18 [0.05, 0.69]
1.4.3 Male	1	30	Risk Ratio (M‐H, Random, 95% CI)	0.57 [0.22, 1.50]
1.5 Recurrence of Lesion	1	60	Risk Ratio (M‐H, Random, 95% CI)	0.50 [0.05, 5.22]
1.6 Side Effects	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.6.1 5‐FU 5% plus 1 %	2	150	Risk Ratio (M‐H, Random, 95% CI)	13.23 [2.65, 65.96]
1.6.2 5‐FU 5%	1	90	Risk Ratio (M‐H, Random, 95% CI)	13.83 [0.89, 215.08]
1.6.3 5‐FU 1%	1	60	Risk Ratio (M‐H, Random, 95% CI)	11.00 [1.51, 79.96]